Search PubMed⌕ Search

Biomedical subjects

R Orecchia

Publications and source records attributed to R Orecchia.

At least 91 records · Page 5Linked to original sources
PubMedDate not supplied

3D-conformal radiation therapy in prostate cancer. Technical considerations after 5 years of experience and 334 patients treated at the Istituto Europeo di Oncologia of Milan, Italy.

AIMS AND BACKGROUND: To report the technique of 3D-conformal radiation therapy (3D-CRT) currently used at our Institute for the treatment of prostate cancer with a curative intent. A critical review of the technical aspects of the technique is provided. METHODS AND STUDY DESIGN: Between December 1995 and October 2000, 334 patients with biopsy-proven adenocarcinoma of the prostate were treated with 3D-CRT. All patients were treated in a prone position with 15 MV X-ray beams and a 6-field technique for all but 20 patients, who were treated with a 3-field technique. Patients were simulated with the rectum and bladder empty. To ensure reproducible positioning, custom-made polyurethane foam or thermoplastic casts were produced for each patient. Subsequently, consecutive CT scan slices were obtained. The clinical target volume and critical organs (rectum and bladder) were identified on each CT slice. The beam's eye view technique was used to spatially display these structures, and the treatment portals were manually shaped based on the images obtained. The beam apertures were initially realized by conventional Cerrobend blocks (48 patients), which were replaced in October 1997 by a computer-driven multi-leaf collimator. The total target dose prescribed at the ICRU point is 76 Gy, delivered in 38 fractions and 54 days. The seminal vesicles are excluded at 70 Gy. Dose-volume histograms were obtained for all patients. If more than 30% of the bladder and/or more than 20% of the rectum receive >95% of the prescribed total dose, the treatment plan is judged as unsatisfactory and is adjusted. The dose-volume histogram can be improved by changing the beam's arrangement and/or weights or by introducing or modifying the wedge filters. CONCLUSIONS: 3D-CRT in prostate cancer patients is a highly sophisticated and time-consuming method of dose delivery. Important technical issues remain to be clarified.

Humans↗
PubMedDate not supplied

Number of potential patients to be treated with proton therapy in Italy.

In radiotherapy, the use of proton beams is one of the most promising approaches in order to reduce the treatment volume and, consequently, increase the total dose avoiding severe complications to the normal tissues surrounding the target. Among the new hospital-based facilities that are planned for the next future, the italian project is in an advanced stage of study. Because of the complexity and high cost of the italian centre, one of the most important information in order to establish the cost/benefit balance, is represented by the number of potential patients to be treated for the various pathologies. For this reason it is useful to define a priority scale of clinical indications and, on this basis, to estimate the yearly patient afflux to the center, taking into account the incidence and the expected new cases to be treated with protons. Indications have been divided into two categories, according to decreasing priority. Category A includes all the tumors in which the use of proton therapy has clearly demonstrated to be advantageous, being the only way to give a curative dose to the target. In Italy, the estimated number of this category of patients is 825 each year. Category B comprises a great variety of tumors characterized mainly by a local evolution, with a limited likelihood of distant spread, and therefore potentially cured if the local control can be obtained. The total number of potential patients in this category is more than 10,000.

Humans↗
PubMedDate not supplied

Review of current protocols for protontherapy in USA.

The basis for interest in proton beams by clinical radiation oncologists lies in reduction in treatment volume. The yields from employing a smaller treatment volume are the increase of tumor control probability and the reduction of normal tissues complication probability. The clinical use of proton therapy began in 1954 at Uppsala University in Sweden and in 1961 at Harvard Cyclotron Laboratory in Boston, USA. So far, the total number of worldwide patients treated by protons is about 20,000. In this paper attention will be given to the treatment of patients at the Massachusetts General Hospital-Massachusetts Eye and Ear Infirmary-Harvard Cyclotron Laboratory, and at the Loma Linda University Medical Center. In particular, a review of the literature about the techniques and the results of treatment of skull base and cervical spine chordoma and low-grade chondrosarcoma, skull base meningioma, pituitary tumors, paranasal sinus carcinoma, glioblastoma multiforme, artero-venous malformations, uveal melanoma, macular degeneration, retinoblastoma, thoracic spine-sacrum tumors, and prostate carcinoma is presented. In order to verify and improve the clinical results, the conduct of prospective trials on an inter-institutional basis is essential. To facilitate the conduct of such studies the US National Cancer Institute and the American College of Radiology have established the Proton Therapy Oncology Group (PROG). Several phase III and some phase I-II trials are active at the Massachusetts General Hospital, Harvard Cyclotron Laboratory, and at the Loma Linda University Medical Center.

Clinical Protocols↗
PubMedDate not supplied

Surgery or radiotherapy for early stages carcinomas of the glottic larynx.

AIMS AND BACKGROUND: The choice of treatment in limited squamous cell carcinoma of the glottic larynx often depends on individual and tumor factors. Data of the literature clearly show that surgery and radiotherapy tend to give identical results in terms of survival. We examined 196 cases of T1-T2/N0 cancers of the glottic larynx. We review the literature and discuss the indications and the efficacy of the various available treatments. METHODS AND STUDY DESIGN: 196 consecutive cases of T1-T2/N0 cancers of the glottic larynx were examined. In 54.5% the tumor was confined to the vocal cord; in 38.2% it extended to the anterior commissure, in 4.6% to the arytenoid cartilage and in 2.5% to the floor of the ventricle. We performed partial laryngeal surgery in 41.3% (81 cases). Radiotherapy alone was employed in 58.6% (115 cases). RESULTS: In T1a and T1b cases there was no statistically significant difference in 5-year disease-free survival. In T2 cases the NED survival of patients who underwent partial laryngectomies (90% of cases) was significantly better (P <0.05) than among patients given radiotherapy (73%). NED survival at 5 years in patients with the primary tumor on a vocal cord, ventricle or anterior commissure was 78%, 80% and 81%, respectively, with no statistically significant difference among the various sites. It is possible that involvement of the anterior commissure exposes patients to greater risk of recurrence when radiotherapy alone is used (5 out of 23 cases, 21.7%, compared to 3 out of 52 cases, 5.7%, among our surgically treated patients). CONCLUSIONS: When the tumor is confined to the vocal cord and mobility is not impaired (T1a), surgery and radiotherapy give comparable results, and the latter yields a better functional outcome. When the anterior commissure is involved, recurrences appear to be less likely after surgery. In T2 glottic carcinoma, surgery gives better results than radiotherapy alone. In any event, the choice of treatment should be patient-specific and based on a careful analysis of the factors involved in each case.

Adult↗
PubMedDate not supplied

[Automatic opto-electronic control of patient position in radiotherapy for breast carcinoma].

INTRODUCTION: We report on the technical and clinical validation of a system for real-time analytical control of patient position at simulation and treatment units in radiotherapy. MATERIAL AND METHODS: The positioning control system uses a technology for motion analysis consisting of an optical component (a pair of TV cameras) and of a unit for real-time image processing. The system can provide real-time (up to 100 times a second) three-dimensional (3D) coordinates of a set of passive markers (small plastic hemispheres, 5 mm O) previously positioned on the patient and located within the field of view of the system's TV cameras. The method for positioning quality control is based on the analytical comparison between the current positions of the set of markers placed on the patient's skin and a corresponding reference pattern, the latter acquired at the end of the simulation procedure or at the first irradiation session. The system was used at the Radiotherapy Division of the European Institute of Oncology for the analytical control of repositioning in three patients submitted to irradiation after conservative surgery (quadrantectomy) for breast cancer. This showed the clinical feasibility of both the technology and the method, and permitted to quantify improvement in patient positioning relative to current repositioning procedures. In particular, the possibility to evaluate the patient's breathing phases allowed to distinguish the different factors (repositioning inaccuracies and cyclic and random patient movements) contributing to global localization errors. RESULTS: This method is independent of physical and geometrical irradiation parameters and permits efficient real-time quantitative control of specific repositioning quality and of actual patient immobility during irradiation. Assessment of the accuracy of conventional repositioning methods based on laser alignment showed a fair performance of the optical centering procedure (with 3D displacements < 5 mm) only for the markers placed close to the skin landmarks used for laser alignment. On the contrary, the markers within the irradiation field but not directly controlled during the repositioning procedure exhibited localization errors > 5 mm; this happened even though the inaccuracies related to patient's breathing movements had been excluded from analysis. Moreover, quantitative assessment of global localization errors confirmed the high influence of breathing movements on the position repeatability and maintenance. In this case, even the markers which were on average well repositioned turned out to be significantly displaced during the radiation dose delivery. CONCLUSIONS: Our results confirm that real-time motion analysis based on opto-electronic techniques can play a crucial role as a means of improving patient positioning and assessing immobility. Thus, the system permits to quantify errors in target volume localization, which permits to adopt suitable countermeasures to reduce uncertainties during actual irradiation. This is a crucial requirement, particularly when the complexity of the irradiation geometry (conformal radiotherapy) or radiation type (hadrontherapy) calls for optimal application of the simulated treatment plan to each actual irradiation session.

Breast Neoplasms↗
PubMedDate not supplied

[Modification of vestibular function after radiation therapy for head and neck tumors].

The effect of radiation on the vestibular apparatus of animals and man have not been widely investigate. Referred symptoms are disequilibrium and spontaneous nystagmus in animals while histological features are intralabyrinthic haemorrhage, edema of the endolymphatic spaces and alterations of sensory hair cells. A group of 20 patients with head and neck cancer located in different sites (nasal cavity, oropharynx, oral cavity, parotid gland) underwent to vestibular investigations before and 3-6 months after radiation therapy. Ten patients (50%) showed an alteration of the vestibular function of peripheral origin after radiation treatment. Complications appeared from a few weeks up to several months following termination of radiotherapy. The slow development of the lesion permitted central compensation. Few patients had symptoms and vestibular symptomatology was always of secondary importance with respect to the initial pathology.

Adult↗
PubMedDate not supplied

[Cell kinetic analysis and treatment planning in epidermoid tumors of the head and neck].

Cell kinetic parameters were evaluated using the method based on in vivo incorporation of Bromodeoxyuridine (BrdU) and flow cytometric (FCM) analysis in 30 human epidermoid head and neck tumors from oropharynx, oral cavity, rhinopharynx, larynx and lips. BrdU was injected four/six hours before the obtainment of multiple bioptic samples from the tumor tissues. The flow cytometric method was carried out on 70% ethanol fixed cell suspensions based on established protocol for the simultaneous evaluation of DNA content and BrdU uptake using anti-BrdU monoclonal antibodies. We have evaluated the following FCM parameters: DNA ploidy, the degree of DNA aneuploidy (DNA index), Labelling Index (LI), duration of s-phase (Ts) and tumor potential doubling time (Tpot). LI values ranged from 1.5 to 20% with a median value of 10%. The median LI of DNA diploid tumors was 5.4% compared to 14% in DNA aneuploid tumors. Ts values ranged from 8 to 11, the median value being 10 hours. Tpot values ranged from 2 days to 16 days, the median Tpot being 5 days. The large heterogeneity of all these parameters indicates that these tumors may have a different degree of biologic aggressiveness (9). Tpot values did not correlate with DNA ploidy nor with lymph node metastasis status. Tpot values did not correlate in a statistically significant manner with degree of differentiation although shorter Tpot were more frequently observed in moderate or poorly differentiated tumors. Our study shows that the FCM-BrdU technique in vivo is feasible in a clinical setting to evaluate the proliferative behaviour of head and neck tumors, before any specific therapeutic decision is taken after surgery is performed. It is likely that tumors with more aggressive biological behavior, as indicated by LI > 15%, DNA aneuploidy and Tpot < 5 days, may benefit from more aggressive therapies such as accelerated regimeus of radiotherapy and/or other multimodal therapies in respect to tumors with slow growth rate (LI < 15%), DNA diploidy and Tpot > 5 days. So far, however, it still remains to be demonstrated from randomized clinical trials if the knowledge of such individualized cell Kinetic parameters really can help to choose the most effective therapy for every individual patient.

Bromodeoxyuridine↗
PubMedDate not supplied

[Recurrence after radiotherapy and/or surgery of carcinoma of the oropharynx and the pharynx. Possibilities of salvage surgery].

Forty-seven laryngeal and 21 oropharyngeal recurrences were treated with salvage surgery alone or combined with radiotherapy at the ENT Clinic and Radiotherapy Division of the University of Turin, Italy. Primary tumors had been treated with surgery alone in 10 cases (larynx) and in 21 cases (oropharynx), with combined surgery and radiotherapy in 2 and 8 patients, and with radiotherapy alone in 9 and 18 cases. We observed 26/47 (larynx) and 12/21 (oropharynx) recurrences at the site of primary tumor, 20/47 and 9/21 in loco-regional nodes, and 9/47 and 3/21 in locations adjacent to the primary tumor. Salvage treatment employed surgery alone in 12 (oropharynx) and 16 (larynx) cases; radiotherapy was combined in 9 and 31 cases. Five-year actuarial NED survival was 45.5% for laryngeal and 24% for oropharyngeal cancer patients. After salvage surgery, 50% of laryngeal lesions and only 25% of oropharyngeal recurrences were completely cured. In our series, in 2 cases only the complications caused the patient's death, while in the extant cases a prolonged postoperative hospitalization was necessary. Our study was aimed at investigating the curative potentials of secondary therapy for recurrent carcinomas. A review of the literature on the subject is reported. The small amount of published data prevents "universal" treatment protocol from being assessed. The authors suggest the opportunity of employing a multimodal treatment policy for recurrences of head and neck cancers.

Adult↗
PubMedDate not supplied

[Radiologic hyperthermia with microwaves and radio-frequencies. I. Presentation of a multifrequency system].

A computerized system with automatic treatment parameters control for radiological hyperthermia, called Sapic SVO3, is presented. The system has been planned and built by the "Sezione Avionica ed Equipaggiamenti" of the Aeritalia in cooperation with the Radiotherapy Department of the University of Turin. The device is supplied with a multifrequency generator system (915, 433, 2-30 MHz) connected with many kinds of applicators (microstrip antennas, high constant dielectric material loaded antennas, waveguide antennas), with a fiber optic system for temperature control and with a previsional thermometry system.

Computers↗
PubMedDate not supplied

[Radiologic hyperthermia with microwaves and radiofrequencies. II. Results in 57 neoplastic recurrences].

The authors present their results with hyperthermic treatment (alone or associated with radiation therapy) on 43 patients (with a total of 57 sites) treated from september 1983 to august 1985. All patients had recurrent lesion of pretreated malignant tumors. Among these there were brest adenocarcinomas, squamous cell carcinomas of head and neck, melanomas and soft tissues sarcomas. The clinical protocol was: hyperthermia alone (43 degrees-45 degrees C during 30 minutes) twice weekly (for a total of 8-10 treatments) or hyperthermia plus radiation therapy (4 Gy/fraction) for a total of 6-8 seances. In summary the response rate (CR + PR) was 80.4% (RT + HT 90% - HT alone 67.5%); the complete response rate was 24.5%.

Adult↗
PubMedDate not supplied

[Results of interstitial curietherapy and combined transcutaneous radiotherapy-curietherapy in 150 patients with carcinoma of the tongue and/or mouth floor].

The authors report their experience on the treatment of carcinoma of the oral tongue and floor of the mouth with interstitial brachytherapy, alone or in combination with external irradiation. One hundred and fifty patients were treated; among these, 116 with brachytherapy alone, 34 with combined treatment. The five years local control in those patients treated with brachytherapy alone was 72.5% in T1, 61.2% in T2 and 35% in T3; in those patients treated with external irradiation and brachytherapy the global five years control was 42.5%. The global five years survival was 64% in the patients treated with brachytherapy alone and 48% in the patients treated with combined therapy.

Adult↗
PubMedDate not supplied

[Percutaneous treatment of hilar cholangiocarcinoma completed by high-dose rate brachytherapy. Experience in the first 5 cases].

Cholangiocarcinoma at the confluence of the hepatic ducts (Klatskin tumor) is a slowly growing malignancy with early onset of symptoms and poor outcome since surgery allows radical resection in only a minority of cases. Percutaneously placed biliary stents offer a good palliation, but tend to obstruct after 6-8 months; then, retreatment requires exchange of the endoprosthesis or establishment of a permanent external-internal biliary drainage which offers, in some patients, a relatively long survival. Percutaneous intraluminal HDR brachytherapy might be a valid alternative as a definitive therapy or as a method to keep metallic stents patent for a long time. Five patients with hilar cholangiocarcinoma, diagnosed by means of ultrasound, Computed Tomography, percutaneous transhepatic cholangiography and transluminal biopsy, underwent double percutaneous external-internal biliary drainage. Dummy sources were introduced into the drainage catheters to allow dose distribution planning. The stepwise progression of the miniaturized high activity Iridium source inside the applicators, introduced into the drainage catheters, was controlled and monitored by a computer equipped with dedicated software. In the radiotherapy bunker, using the remote loading technique, percutaneous intracavitary high dose rate brachytherapy was delivered at the rate of 750 cGy per fraction, prescribed at 1 cm from the center of the catheter, once a week, for 4 weeks. Nevertheless, only 4 of 5 patients underwent the complete treatment. In one case, radiation treatment was discontinued after the first session because of digestive bleeding from a duodenal ulcer, supposingly as a consequence of the decubitus of a catheter tip. CT demonstrated rapid progression of the disease with neoplastic spread to the omentum and gallbladder wall thickening; a gallbladder malignancy was then suspected and the patient was no more eligibile for brachytherapy. Subsequently, Carey-Coons endoprostheses were inserted to prevent post-actinic strictures and removed after three months. After completing radiation therapy, control cholangiograms demonstrated in all cases improvement of neoplastic strictures. The first two patients we treated show no signs of tumor recurrence at 4 and 1 months, respectively, after endoscopic removal of the stents. The third patient is still bearing 2 Carey-Coons endoprostheses to be removed after 3 months. The last patient with supposingly partial success of bracytherapy, was treated with two Strecker nitinol stents.

Aged↗
PubMedDate not supplied

[Long-term survival following chemotherapy for recurrent head and neck cancer: patient characteristics].

Eighty-one patients with recurrent squamous cell carcinoma of the head and neck (60 patients) or undifferentiated carcinoma of the nasopharyngeal type (21 patients) were treated with cisplatin (80-100 mg/m2iv d1) and 5-fluorouracil (750-1000 mg/m2Cl d1-5). In squamous cell carcinoma patients there were 7 complete responses (11.6%), 25 partial responses (41.7%), 20 stable disease situations (33.3%) and 8 progressions (13.3%). In nasopharyngeal carcinoma patients there were 6 complete responses (28.6%), 9 partial responses (42.8%), 3 stable disease situations (14.3%) and 3 progression (14.3%). There were 5/60 patients (8.3%) with disease-free survival > 18 months in the squamous cell carcinoma group and 2/21 (9%) in the nasopharyngeal carcinoma group. All long-term survival patients had the following characteristics: good performance status (0-1 ECOG scale), disease- free interval from the first treatment > 12 months, local non-bulky relapse (rT1-2). A re-irradiation with palliative doses (20-48 Gy) was conducted in 3/7 patients. This treatment may have improved the response to drugs with regard to length and quality.

Adult↗
PubMedDate not supplied

[Definition of the T parameter in nasosinusal neoplasms: a CT-MR comparison].

This study was aimed at investigating the value of CT and MRI in the staging of sinonasal tumors. The authors report 22 cases of sinonasal tumors: 7 squamous cell carcinomas, 4 adenoid-cystic carcinomas, 1 mucoepidermoid carcinoma, 6 adenocarcinomas, 1 esthesioneuroblastoma, 1 osteosarcoma, 1 small-cell sarcoma and finally 1 non-Hodgkin lymphoma. No significant differences were observed between CT and MR staging: 2 T2 and 15 T4 lesions were diagnosed in the maxillary sinuses and 3 stage-II and 1 stage-III lesions in the naso-ethmoidal region. Tumor spread was similar in 20/22 cases: MRI excluded the involvement of maxillary and sphenoid sinuses in 2 cases. CT was superior in the assessment of bone destruction particularly at the base of the skull, but MRI better demonstrated intracranial spread. MRI detailed the intraorbital muscles and, in the infratemporal fossa, the pterygoid muscles better than CT. High agreement was observed between CT and histology in 5/7 cases and between MRI and histology in 6/7 cases undergoing craniofacial resection. Seventeen of 22 cases had low to intermediate signal intensity on T1-weighted, PD and T2-weighted MR images. Signal was hyperintense in 5 cases: 1 adenocarcinoma with mucinous features, 3 adenoid-cystic carcinomas and 1 esthesioneuroblastoma. In agreement with literature data, this study confirms CT as the examination of choice in staging sinonasal tumors: nonetheless, MRI yields valuable information in the cases with tumor spread to the muscles and soft tissues.

Adult↗